Accesswire
12 Aug 2026, 11:40 UTC · 9w ago
Impact · against what's priced in
DataMeds AI (MEDS) has established a quantitative revenue baseline and entered the high-demand GLP-1 market, providing a concrete foundation for growth. The upcoming public launch of the Health Lives Here app in September significantly expands the company's total addressable market beyond a niche athlete group.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Corexa Pharmacy has enabled access to oral and injectable GLP-1 agonist drugs, including Foundayo and oral Wegovy.
More positive than 94% of claims this week
The 'Health Lives Here' app, integrated with Corexa's online store, will launch to the general public in September 2026.
Continue reading
5 related stories
The company established a $7 million annualized revenue run rate and secured access to GLP-1 drugs and companion medical foods, while preparing to move its telemedicine app from a niche NFL alumni group to the general public in September.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 88% of claims this week
July 2026 revenue for Corexa Pharmacy exceeded $600,000, establishing an annualized run rate above $7 million.
So whatProvides a quantitative baseline for valuation and proves the business model has stabilized following rebranding.
More positive than 80% of claims this week
The company launched Forzet, a medical food specifically designed to manage muscle loss associated with GLP-1 therapies.
So whatCreates a high-margin cross-selling opportunity by bundling companion products with primary weight-loss medications.
More positive than 67% of claims this week
Which stocks this story touches
More positive than 90% of ticker scores this week
The company reported stabilized revenue, the completion of app integration, and strategic expansions into GLP-1 drugs and telemedicine.
More positive than 53% of ticker scores this week
Mentioned as a provider of drugs being distributed through the company's pharmacy network, indicating steady demand.
More positive than 53% of ticker scores this week
Mentioned as a provider of drugs being distributed through the company's pharmacy network, indicating steady demand.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
WSJ
47m ago
More positive than 11% of relationship scores this week
[a_to_b] DataMeds AI's pharmacy division offers patients access to Novo Nordisk's oral Wegovy.
+111.2%
Price agrees with the score
$2.94 vs $1.39 close before publication (Aug 11) · not market-adjusted
MEDS chart →
